JP-11646
JP-11646 is a pan-PIM inhibitor with increased potency against PIM2 (IC50 = 0.5 nM) . JP11646 is freely reversible and ATP non-competitive. JP-11646 results in a decrease of PIM1, 2, and 3 mRNA. JP-11646 can effectively inhibit cell viability in small cell lung cancer (SCLC) and large cell neuroendocrine carcinomas of the lung (LCNEC) . JP-11646 can cause a decrease in p-4EBP-1 protein, increasing the cleavage of caspases while decreasing caspase-3. JP-11646 induces apoptosis or necroptosis in cells. JP-11646 leads to reductions in MYC paralogs. JP-11646 can be used for the study of SCLC, LCNEC, human acute leukemia (AML), multiple myeloma (MM), and triple-negative breast cancer (TNBC) [1][2][3][4][5].
Product Specifications
CAS Number
1902983-63-4
UNSPSC
12352100
Target
Apoptosis; Caspase; Necroptosis; NF-κB; PARP; Pim
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; NF-κB
Field of Research
Cancer
Smiles
O=C1NC(/C(S1)=C/C2=CC=NC(N[C@H]3CC[C@@H](CC3)NCC4=CC=CC5=C4C=CC=C5)=N2)=O
Molecular Formula
C25H25N5O2S
Molecular Weight
459.56
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Caspase 3; NF-κB; PIM2
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
